The Italian guidelines for patients with serious VAP recommend treatment with the newer beta-lactam–beta-lactamase inhibitors or cefiderocol for CR, MDR, and extensively drug-resistant (XDR) Gram-negative bacterial infections, with agent selection based on the mechanism of resistance [53]. The gene discussed is LACTB; the disease is gram-negative bacterial infections.